Posted on May 31st, 2009 by Health News
GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab [...]
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
Bayer Healthcare Pharmaceuticals Inc. announced that several studies evaluating the use of Leukine(R) (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. “We are excited to see that several studies of Leukine have been accepted at ASCO,” said Pam Cyrus, MD, vice president, Medical Affairs, Oncology, [...]
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint — that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last [...]
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
Perceptive Informatics, the industry’s leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced the launch of a website designed to help investigators apply the new 1.1 version of RECIST (Response Evaluation Criteria In Solid Tumors) in medical imaging-based oncology trials.
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
CuraGen Corporation (Nasdaq: CRGN) announced plans for three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
Surprisingly few pharmacies in the U.S. are able to translate prescription medication instructions into Spanish, making it difficult for patients who speak only Spanish to understand how to take their medications properly, according to a new study from the Northwestern University Feinberg School of Medicine.
No Comments »
Filed under: Pharmacy News
Posted on May 31st, 2009 by Health News
UroToday.com - This updated review of tadalafil (Cialis), one of the three available phosphodiesterase type 5 (PDE5) inhibitors that revolutionized the treatment of erectile dysfunction (ED), analyzes its latest clinical studies. Tadalafil’s most unique and identifying characteristic is its long half-life of 17.5 hours, compared with 4 hours for sildenafil (Viagra) and vardenafil [...]
No Comments »
Filed under: Men's Health
Posted on May 30th, 2009 by Health News
WASHINGTON (MedPage Today) — A new FDA report suggests that products containing acetaminophen carry stronger label warnings about the drug’s potential for liver damage.
No Comments »
Filed under: General Health News
Posted on May 30th, 2009 by Health News
CHICAGO (MedPage Today) — Environmental pollution may be contributing to the growing incidence of liver disease in the general U.S. population, researchers found.
No Comments »
Filed under: General Health News
